- Home
- SVRA vs CION Comparison
SVRA vs CION Comparison
Compare SVRA & CION Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SVRA
- CION
- Stock Information
- Founded
- SVRA N/A
- CION 2011
- Country
- SVRA United States
- CION United States
- Employees
- SVRA N/A
- CION N/A
- Industry
- SVRA Biotechnology: Pharmaceutical Preparations
- CION Finance/Investors Services
- Sector
- SVRA Health Care
- CION Finance
- Exchange
- SVRA Nasdaq
- CION Nasdaq
- Market Cap
- SVRA 590.4M
- CION 626.1M
- IPO Year
- SVRA N/A
- CION N/A
- Fundamental
- Price
- SVRA $3.23
- CION $11.66
- Analyst Decision
- SVRA Buy
- CION Hold
- Analyst Count
- SVRA 7
- CION 2
- Target Price
- SVRA $9.86
- CION $12.25
- AVG Volume (30 Days)
- SVRA 1.4M
- CION 339.1K
- Earning Date
- SVRA 11-12-2024
- CION 11-07-2024
- Dividend Yield
- SVRA N/A
- CION 12.36%
- EPS Growth
- SVRA N/A
- CION 50.69
- EPS
- SVRA N/A
- CION 1.48
- Revenue
- SVRA N/A
- CION $254,537,000.00
- Revenue This Year
- SVRA N/A
- CION $0.86
- Revenue Next Year
- SVRA N/A
- CION N/A
- P/E Ratio
- SVRA N/A
- CION $7.89
- Revenue Growth
- SVRA N/A
- CION 3.26
- 52 Week Low
- SVRA $2.82
- CION $10.52
- 52 Week High
- SVRA $5.70
- CION $12.69
- Technical
- Relative Strength Index (RSI)
- SVRA 45.22
- CION 51.27
- Support Level
- SVRA $2.99
- CION $11.45
- Resistance Level
- SVRA $3.36
- CION $11.92
- Average True Range (ATR)
- SVRA 0.23
- CION 0.20
- MACD
- SVRA -0.02
- CION 0.01
- Stochastic Oscillator
- SVRA 28.74
- CION 49.25
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
About CION CION Investment Corporation
CION Invt Corp is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company. The Company's portfolio is comprised of investments in senior secured debt, including first lien loans, second lien loans and unitranche loans, and, to a lesser extent, collateralized securities, structured products and other similar securities, unsecured debt, and equity, of private and thinly-traded U.S. middle-market companies.